The current state of RAAS blockade in the treatment of hypertension and proteinuria (Q37623107)

21 August 2017

1 reference

title

The current state of RAAS blockade in the treatment of hypertension and proteinuria (English)

1 reference

21 August 2017

arterial hypertension

0 references

author name string

Rigas G Kalaitzidis

series ordinal

1

1 reference

PubMed ID

19863868

21 August 2017

George L Bakris

series ordinal

2

1 reference

21 August 2017

1 November 2009

1 reference

Current cardiology reports

21 August 2017

1 reference

21 August 2017

11

1 reference

21 August 2017

436-442

1 reference

21 August 2017

6

1 reference

https://scigraph.springernature.com/pub.10.1007/s11886-009-0063-3

21 August 2017

0 references

cites work

Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11886-009-0063-3

Microalbuminuria and chronic kidney disease as risk factors for cardiovascular disease

21 January 2018

1 reference

12 December 2020

Lack of association between endothelial nitric oxide synthase gene polymorphisms, microalbuminuria and endothelial dysfunction in hypertensive men

1 reference

12 December 2020

Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes

1 reference

12 December 2020

Glomerular Filtration Rate, Cardiorenal End Points, and All-Cause Mortality in Type 2 Diabetic Patients

1 reference

12 December 2020

Influence of microalbuminuria in achieving blood pressure goals

1 reference

12 December 2020

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

1 reference

12 December 2020

Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis

1 reference

12 December 2020

Aliskiren combined with losartan in type 2 diabetes and nephropathy

1 reference

12 December 2020

Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection

1 reference

12 December 2020

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)

1 reference

12 December 2020

Changes in insulin sensitivity, renal function, and markers of endothelial dysfunction in hypertension--the impact of microalbuminuria: a 13-year follow-up study

1 reference

12 December 2020

Blood pressure and end-stage renal disease in men

1 reference

12 December 2020

Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial

1 reference

12 December 2020

Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study

1 reference

12 December 2020

Hypertensive nephrosclerosis

1 reference

12 December 2020

Prevalence of chronic kidney disease in the United States

1 reference

12 December 2020

Albuminuria Is a Target for Renoprotective Therapy Independent from Blood Pressure in Patients with Type 2 Diabetic Nephropathy: Post Hoc Analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Trial

1 reference

12 December 2020

KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease.

1 reference

12 December 2020

The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension

1 reference

12 December 2020

Efficacy and safety of benazepril for advanced chronic renal insufficiency

1 reference

12 December 2020

Antihypertensive therapy in the presence of proteinuria

1 reference

12 December 2020

Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency

1 reference

12 December 2020

Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review

1 reference

12 December 2020

Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).

1 reference

12 December 2020

Influence of albuminuria and glomerular filtration rate on blood pressure response to antihypertensive drug therapy

1 reference

12 December 2020

2007 Guidelines for the Management of Arterial Hypertension

1 reference

12 December 2020

Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLH

1 reference

12 December 2020

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

1 reference

12 December 2020

Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study

1 reference

12 December 2020

The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study

1 reference

12 December 2020

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

12 December 2020

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

1 reference

12 December 2020

Telmisartan, ramipril, or both in patients at high risk for vascular events

1 reference

12 December 2020

Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial

1 reference

12 December 2020

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

12 December 2020

Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis

1 reference

12 December 2020

Renin-angiotensin blockade and kidney disease

1 reference

12 December 2020

K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease

1 reference

12 December 2020

Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria

1 reference

12 December 2020

Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease

1 reference

12 December 2020

Predictors of hyperkalemia risk following hypertension control with aldosterone blockade

1 reference

12 December 2020

Controversy about COOPERATE ABPM trial data

1 reference

12 December 2020

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

12 December 2020

10.1007/S11886-009-0063-3

Identifiers

DOI

1 reference

21 August 2017

1 reference

PubMed ID

19863868